The Stem Cells and Cardiovascular Development lab run by Dr Nathan Palpant uses human pluripotent stem cells (hPSCs), genomics, genome editing, and disease modelling to study mechanisms controlling cardiovascular development and disease.

Cardiovascular disease is the leading cause of death worldwide and new therapeutics are required to address growing public health demands. Expanding treatment options for cardiovascular diseases requires interdisciplinary research from developmental biology to translation.

To this end, Dr Palpant leads functional genomics and epigenetic studies at single cell resolution and across diverse cardiac and vascular fates to determine the genetic basis of cell identity and fate.

His team is developing stem cell models of disease for drug discovery. They are also building links with clinician/researchers bringing together stem cell biology, mechanical-assist devices, and large animal disease models to identify new approaches to address cardiovascular disease.

Read more

Discover more

Researcher biography

Dr Nathan Palpant completed a BSc in Biology (magna cum laude) from Whitworth University in 2001 and a PhD in Molecular and Integrative Physiology from the University of Michigan in 2009. He then completed a postdoctoral fellowship at the University of Washington Institute for Stem Cell and Regenerative Medicine in 2015 studying the genetic and signaling basis of lineage decisions in cardiovascular development. In 2015 he was recruited as Group Leader at the University of Queensland's Institute for Molecular Bioscience where he now heads the Stem Cell and Cardiovascular Development Laboratory. His laboratory focuses on mechanisms underlying mesoderm cell lineage decisions using human pluripotent stem cells, genomics, genome engineering, and bioengineering.